Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
NOV
NOV
$7.45B
| $408K | ﹤0.01% |
10,910
-1,128,300
| -99% | -$41.1M |
|
|
MMAC
2827
DELISTED
MMA Capital Holdings, Inc. Common Stock
MMAC
| $408K | ﹤0.01% |
21,462
+2,795
| +15% | +$49.9K |
|
2828
Phibro Animal Health
PAHC
$1.37B
| $407K | ﹤0.01% |
+13,900
| New | +$379K |
|
|
LSBG
2829
DELISTED
Lake Sunapee Bank Group
LSBG
| $406K | ﹤0.01% |
+17,200
| New | +$353K |
|
|
GLOG
2830
DELISTED
GASLOG LTD
GLOG
| $404K | ﹤0.01% |
+25,100
| New | +$399K |
|
2831
Wave Life Sciences
WVE
$1.02B
| $403K | ﹤0.01% |
+15,400
| New | +$501K |
|
2832
Smith Micro Software
SMSI
$17M
| $402K | ﹤0.01% |
6,403
+650
| +11% | +$43.1K |
|
2833
Unity Bancorp
UNTY
$619M
| $402K | ﹤0.01% |
25,601
+8,300
| +48% | +$113K |
|
|
SBCP
2834
DELISTED
Sunshine Bancorp, Inc
SBCP
| $401K | ﹤0.01% |
+23,400
| New | +$368K |
|
2835
Taylor Devices
TAYD
$172M
| $400K | ﹤0.01% |
26,300
-4,000
| -13% | -$61.4K |
|
2836
Veru
VERU
$46M
| $400K | ﹤0.01% |
43,950
-1,770
| -4% | -$18.3K |
|
|
VIRX
2837
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $400K | ﹤0.01% |
3,159
+457
| +17% | +$63.6K |
|
|
SANW
2838
DELISTED
S&W Seed Co
SANW
| $398K | ﹤0.01% |
4,553
+864
| +23% | +$79.5K |
|
2839
NanoViricides
NNVC
$34.9M
| $397K | ﹤0.01% |
18,530
+1,315
| +8% | +$35.1K |
|
2840
Immersion
IMMR
$247M
| $392K | ﹤0.01% |
+36,913
| New | +$348K |
|
2841
Federal Signal
FSS
$7.71B
| $390K | ﹤0.01% |
25,000
-241,300
| -91% | -$3.48M |
|
2842
Lifecore Biomedical
LFCR
$181M
| $388K | ﹤0.01% |
+28,082
| New | +$389K |
|
|
CMD
2843
DELISTED
Cantel Medical Corporation
CMD
| $386K | ﹤0.01% |
4,900
-21,425
| -81% | -$1.66M |
|
2844
SiNtx Technologies
SINT
$10.9M
| – | – |
0
| – | – |
|
2845
Lindblad Expeditions
LIND
$2.24B
| $384K | ﹤0.01% |
40,600
-11,200
| -22% | -$102K |
|
|
GTLS
2846
DELISTED
Chart Industries
GTLS
| $382K | ﹤0.01% |
10,600
-27,400
| -72% | -$934K |
|
|
AINC
2847
DELISTED
Ashford Inc.
AINC
| $379K | ﹤0.01% |
8,780
+1,100
| +14% | +$48.1K |
|
2848
Ohio Valley Banc Corp
OVBC
$211M
| $378K | ﹤0.01% |
13,900
+2,500
| +22% | +$61.6K |
|
|
CCLP
2849
DELISTED
CSI Compressco LP
CCLP
| $376K | ﹤0.01% |
38,593
+16,793
| +77% | +$170K |
|
|
CHKR
2850
DELISTED
CHESAPEAKE GRANITE WASH TRUST
CHKR
| $376K | ﹤0.01% |
+160,073
| New | +$353K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.